FGFR1 fusions as a novel molecular driver in rhabdomyosarcoma Journal Article
| Authors: | de Traux De Wardin, H.; Cyrta, J.; Dermawan, J. K.; Guillemot, D.; Orbach, D.; Aerts, I.; Pierron, G.; Antonescu, C. R. |
| Article Title: | FGFR1 fusions as a novel molecular driver in rhabdomyosarcoma |
| Abstract: | The wide application of RNA sequencing in clinical practice has allowed the discovery of novel fusion genes, which have contributed to a refined molecular classification of rhabdomyosarcoma (RMS). Most fusions in RMS result in aberrant transcription factors, such as PAX3/7::FOXO1 in alveolar RMS (ARMS) and fusions involving VGLL2 or NCOA2 in infantile spindle cell RMS. However, recurrent fusions driving oncogenic kinase activation have not been reported in RMS. Triggered by an index case of an unclassified RMS (overlapping features between ARMS and sclerosing RMS) with a novel FGFR1::ANK1 fusion, we reviewed our molecular files for cases harboring FGFR1-related fusions. One additional case with an FGFR1::TACC1 fusion was identified in a tumor resembling embryonal RMS (ERMS) with anaplasia, but with no pathogenic variants in TP53 or DICER1 on germline testing. Both cases occurred in males, aged 7 and 24, and in the pelvis. The 2nd case also harbored additional alterations, including somatic TP53 and TET2 mutations. Two additional RMS cases (one unclassified, one ERMS) with FGFR1 overexpression but lacking FGFR1 fusions were identified by RNA sequencing. These two cases and the FGFR1::TACC1-positive case clustered together with the ERMS group by RNAseq. This is the first report of RMS harboring recurrent FGFR1 fusions. However, it remains unclear if FGFR1 fusions define a novel subset of RMS or alternatively, whether this alteration can sporadically drive the pathogenesis of known RMS subtypes, such as ERMS. Additional larger series with integrated genomic and epigenetic datasets are needed for better subclassification, as the resulting oncogenic kinase activation underscores the potential for targeted therapy. © 2024 Wiley Periodicals LLC. |
| Keywords: | adult; child; clinical article; school child; young adult; somatic mutation; genetics; pathogenesis; cohort analysis; genetic variability; pathology; histology; dead box protein; dead-box rna helicases; infant; epigenetics; fusion gene; genomics; rhabdomyosarcoma; genetic screening; receptor, fibroblast growth factor, type 1; fibroblast growth factor receptor 1; anaplastic carcinoma; embryonal rhabdomyosarcoma; rhabdomyosarcoma, embryonal; ribonuclease iii; rhabdomyosarcoma, alveolar; fusion; alveolar rhabdomyosarcoma; dicer1 protein, human; epigenomics; fgfr1 protein, human; humans; human; male; female; article; rna sequencing; fgfr1; ank1; tacc1; fgfr1 ank1 gene; fgfr1 tacc1 gene |
| Journal Title: | Genes Chromosomes and Cancer |
| Volume: | 63 |
| Issue: | 4 |
| ISSN: | 1045-2257 |
| Publisher: | Wiley Periodicals, Inc |
| Date Published: | 2024-04-01 |
| Start Page: | e23232 |
| Language: | English |
| DOI: | 10.1002/gcc.23232 |
| PUBMED: | 38607246 |
| PROVIDER: | scopus |
| PMCID: | PMC11385681 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Cristina Antonescu -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work